Patents by Inventor Douglas P. Cerretti

Douglas P. Cerretti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytokine designated lerk-5
    Patent number: 6479459
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: November 12, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • DNA encoding cytokine designated LERK-6
    Patent number: 6472174
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: October 29, 2002
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • TNF-alpha converting enzyme
    Publication number: 20020115175
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Application
    Filed: November 29, 2000
    Publication date: August 22, 2002
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Antibodies that bind the cytokine designated LERK-5
    Publication number: 20020103358
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Application
    Filed: October 15, 2001
    Publication date: August 1, 2002
    Applicant: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Tek antagonists comprising soluble tek extracellular binding domain
    Patent number: 6413932
    Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: July 2, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Luis G. Borges, William C. Farnslow, III
  • TNF-&agr; converting enzyme
    Patent number: 6406877
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: June 18, 2002
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • TNF-a converting enzyme
    Patent number: 6406901
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: June 18, 2002
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Integrin antagonists
    Publication number: 20020042368
    Abstract: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
    Type: Application
    Filed: February 23, 2001
    Publication date: April 11, 2002
    Inventors: William C. Fanslow, Douglas P. Cerretti, Kurt M. Poindexter, Roy A. Black
  • Tek antagonists
    Publication number: 20020039992
    Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
    Type: Application
    Filed: December 7, 2000
    Publication date: April 4, 2002
    Inventors: Douglas P. Cerretti, Luis G. Borges, William C. Fanslow
  • Cytokines that bind the cell surface receptor hek
    Publication number: 20020010325
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Application
    Filed: July 12, 2001
    Publication date: January 24, 2002
    Applicant: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • LERK-5 DNA
    Patent number: 6303769
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: October 16, 2001
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • TNF-alpha converting enzyme
    Publication number: 20010024816
    Abstract: A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Application
    Filed: November 29, 2000
    Publication date: September 27, 2001
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Cytokines that bind the cell surface receptor Hek
    Patent number: 6274117
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: August 14, 2001
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Recombinant cytokine designated LERK-6
    Patent number: 6268482
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: July 31, 2001
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Polynucleotides encoding cytokine designated LERK-5
    Publication number: 20010009768
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Application
    Filed: January 3, 2001
    Publication date: July 26, 2001
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Antibody immunoreactive with a human cytokine designated LERK-6
    Patent number: 6232447
    Abstract: The invention is directed to antibodies immunoreactive with a Human LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: May 15, 2001
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Cytokine designated lerk-6
    Patent number: 6194172
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: February 27, 2001
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • TNF-.alpha. converting enzyme
    Patent number: 6013466
    Abstract: A metalloprotease that converts TNF-.alpha. from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: January 11, 2000
    Assignee: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Antibodies that bind hek ligands
    Patent number: 5969110
    Abstract: Antibodies specific for a hek-L may be generated, using a hek-L polypeptide or fragment thereof as an immunogen. The antibodies may be monoclonal.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: October 19, 1999
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • Cytokine designated LERK-6
    Patent number: RE37582
    Abstract: The invention is directed to LERK-6 as a purified and isolated protein, the DNA encoding the LERK-6, host cells transfected with cDNAs encoding LERK-6.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: March 12, 2002
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti